Combined treatment with SGLT2i and GLP1ra compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry

被引：0
|
作者：
Garcia Vega, D. [1 ]
Cinza-Sanjurjo, S. [2 ]
Eiras, S. [3 ,4 ]
Gonzalez-Juanatey, J. R. [1 ]
机构：
[1] Univ Hosp Santiago de Compostela, Santiago De Compostela, Spain
[2] Ctr Salud Milladoiro, Area Sanitaria Santiago de Compostela, Santiago De Compostela, Spain
[3] Hlth Res Inst Santiago de Compostela, Santiago De Compostela, Spain
[4] CIBERCV, Santiago De Compostela, Spain
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2024年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：591 / 591
页数：1
相关论文
共 50 条
  • [41] Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
    Cersosimo, Angelica
    Salerno, Nadia
    Sabatino, Jolanda
    Scatteia, Alessandra
    Bisaccia, Giandomenico
    De Rosa, Salvatore
    Dellegrottaglie, Santo
    Bucciarelli-Ducci, Chiara
    Torella, Daniele
    Leo, Isabella
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [42] SECTOR OF CARE VARIATIONS IN PRESCRIPTIONS OF SGLT2 INHIBITORS (SGLT2I) AND GLP-1 RECEPTOR AGONISTS (GLP-1 RA) IN THE US MILITARY HEALTH SYSTEM (MHS)
    Nguyen, Julia
    Nee, Robert
    Marneweck, Hava
    Banaag, Amanda
    Koehlmoos, Tracey
    Oliver, James
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2025, 85 (04)
  • [43] Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
    Angelica Cersosimo
    Nadia Salerno
    Jolanda Sabatino
    Alessandra Scatteia
    Giandomenico Bisaccia
    Salvatore De Rosa
    Santo Dellegrottaglie
    Chiara Bucciarelli-Ducci
    Daniele Torella
    Isabella Leo
    Cardiovascular Diabetology, 23
  • [44] Risk-Benefit of SGLT2 Inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in Routine Care of Older Adults
    Patorno, Elisabetta
    Kim, Dae H.
    Pawar, Ajinkya
    Schneeweiss, Sebastian
    Glynn, Robert J.
    Munshi, Medha
    Bessette, Lily G.
    Kim, Seoyoung C.
    DIABETES, 2019, 68
  • [45] Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity
    Terenzi, Daniella C.
    Bakbak, Ehab
    Teoh, Hwee
    Krishnaraj, Aishwarya
    Puar, Pankaj
    Rotstein, Ori D.
    Cosentino, Francesco
    Goldenberg, Ronald M.
    Verma, Subodh
    Hess, David A.
    CARDIOVASCULAR RESEARCH, 2024, 119 (18) : 2858 - 2874
  • [46] Genetic Mimics of GLP-1Ra and SGLT2i Therapy, Heart Failure and Chronic Kidney Disease Outcomes
    Remala, Subbaramireddy
    Liang, Liming
    Shah, Amil
    Buckley, Leo
    CIRCULATION, 2024, 150
  • [47] Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co- transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management
    Kalra, Sanjay
    Bhattacharya, Saptarshi
    Kapoor, Nitin
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2022, 72 (05) : 989 - 990
  • [48] Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes
    Luo, Jing
    Gabriel, Nico
    Korytkowski, Mary
    Hernandez, Inmaculada
    Gellad, Walid F.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 187
  • [49] Glycaemic control and beta cell function in type 2 diabetes on SGLT2i and GLP-1RA combination therapy
    Martinez, R.
    Al-Jobory, H.
    Adams, J.
    Chavez-Velasquez, A.
    Triplitt, C.
    DeFronzo, R. A.
    Cersosimo, E.
    DIABETOLOGIA, 2017, 60 : S408 - S409
  • [50] Anticipating the Impact of 2019 Guidelines: Use of SGLT2i and GLP-1RA in Patients with Diabetes and Cardiovascular Disease
    Rattelman, Cori R.
    Ciemins, Elizabeth L.
    Cuddeback, John K.
    DIABETES, 2019, 68
12345